Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

M and A In Pharmaceutical Contract Manufacturing Industry Report Overview

During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates.

The Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry report provides an analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. It primarily looks at global M&A activity for the pharma CMO industry during 2021–22. Full company acquisitions, facility acquisitions, and the services involved are covered in depth.

M&A Trends ·       Demand for CMO M&A Activity

·       Private Equity

·       Changing Business Environment

Deal Types ·       Company Acquisitions

·       Asset Transactions

·       Mergers

·       Private Equity Deals

Value Chain ·       API

·       Dose Form Manufacturing

·       Packaging

Enquire & Decide

Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

M&A Activity Market Dynamics

Of the deals from 2021–22, around 45% of acquisition targets were API manufacturers, both small molecule and biologic. Biologic API production accounted for a larger quantity of acquisitions, approximately a quarter of deals, despite being the less common capability by far. Additionally, biologic API acquisitions have grown substantially since 2021.

Higher value deals took place in 2021 than in 2022. Russia’s invasion of Ukraine in 2022 significantly added to the inflationary pressures, which were already at play following economies reopening after the pandemic. Rising inflation and interest rates seen in 2022 are likely to have reduced M&A activity, with CMOs showing an increasing reluctance to take on debt. Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production.

CMO Industry - M&A Trends

The main trends that affected M&A activity during 2021–22 were demand for CMO M&A activity, private equity, and changing business environment. CMO M&A increased over 2018–22 (mergers, company acquisitions, private equity investment, and facility acquisitions). Private equity deals and facility acquisitions peaked in 2022. CMO acquisitions peaked in 2021 and declined substantially in 2022, which overall contributed to a slight decline in M&A activity in 2022 compared with 2021.

Top M&A trends in the CMO industry, 2021–22

Top M&A trends in the CMO industry, 2021–22

For more insights into the M&A trends in the CMO industry, download a free report sample

CMO Industry - Deal Types

The key deal types related to the pharma CMO industry are company acquisitions, asset transactions, mergers, and private equity deals. During 2018–22, levels of private equity deals and asset transactions peaked in 2022. The number of CMO acquisitions peaked in 2021 and declined substantially in 2022.

Contract Manufacturing Industry Value Chain

The value chain of the contract manufacturing industry can be simplified into three main segments which are API, dose form manufacturing, and packaging. API is the active component of a drug. In the next layer of the value chain, active and inactive ingredients are combined to produce the final dose form such as a tablet or an injectable. Packaging can be further segmented into primary packaging and secondary packaging. Primary packaging is the placing of a dose form into a container that makes actual physical contact with the drug, while secondary packaging is the placing of a primary package into an outer container.

Contract Manufacturing Industry Value Chain

Contract Manufacturing Industry Value Chain

For more value chain insights into the CMO industry, download a free report sample

Segments Covered in the Report

CMO Industry Deal Types Outlook (2018-2022)

  • Company Acquisitions
  • Asset Transactions
  • Mergers
  • Private Equity Deals

Scope

This report gives important, expert insight you won’t find in any other source. 12 tables and 20 figures throughout the report illustrate major points and trends. This report is required reading for –

  • CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
  • Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
  • Private equity and stock analysts: target identification and analysis, portfolio company performance benchmarking

Reasons to Buy

  • Overview of M&A in the pharma CMO Industry
  • Detailed view of CDMO performance by number of deals, based on GlobalData’s Deals Database
  • Analysis of M&A and private equity investment by target’s specific manufacturing services

3i Group Plc
ABC Farmaceutici SpA
Abu Dhabi Investment Authority
Abzena Ltd
Accutest Research Laboratories (I) Pvt Ltd
ACE Pharmaceuticals BV
Acino International AG
Actylis
AcuraBio Pty Ltd
ADC Biotechnology Ltd
AdhexPharma
ADL BioPharma SLU
ADQ
Adragos Pharma Gmbh
Advent International Corp
Advik Laboratories Ltd
AGC Biologics Inc
Akums Drugs & Pharmaceuticals Ltd
Alcami Corp
Aldevron LLC
Alora Pharmaceuticals LLC
ALS Ltd
Altan Pharma Ltd
Altasciences Co Inc
Alto Partners SGR SpA
Alvotech SA
Ampersand Capital Partners
AmpTec GmbH
ANG Lifesciences India Ltd
ANGUS Chemical Company
ANI Pharmaceuticals Inc
Anjac Health & Beauty
Ankur Drugs and Pharma Ltd. (Inactive)
Anthem Biosciences Pvt Ltd
API Corp
Apnar Pharma LP
Appco Pharma LLC
APR Applied Pharma Research SA
Aragen Life Sciences Pvt Ltd
Arcline Investment Management LP
Ardena Holding NV
Arevipharma GmbH
Arranta Bio
Asahi Kasei Medical Co Ltd
Asahi Songwon Colors Ltd
Ascendia Pharmaceuticals Inc
Ascensus Specialties LLC
Astorg Partners
Astral Steritech Pvt Ltd
AstraZeneca Plc
Astrea SA
Atara Biotherapeutics Inc
Athenex Inc
Atlas Life Sciences Pvt Ltd
Aurex Laboratories LLC
Austrianova Singapore Pte Ltd
Avomeen Analytical Services LLC
Aztiq Pharma Partners
Batavia Biosciences BV
Bayer SA (Brazil)
BBA Capitalpartners Management GmbH
BDR Pharmaceuticals Internationals Pvt Ltd
Beecken Petty O'Keefe & Company
Bio Elpida
BioAgilytix Labs LLC
BioCentriq
Bioconnection BV
Biodextris Inc
BioDuro-Sundia
BioIVT LLC
Bionique Testing Laboratories Inc
Bionova Scientific Inc
Biosynth Ltd
BirgiMefar Group
bluebird bio Inc
Bora Pharmaceuticals Co Ltd
Bristol-Myers Squibb Co
Bureau Veritas SA
Bushu Pharmaceuticals Ltd
Cambrex Corp
Cascade Chemistry
Catalent Inc
Celerion Inc
Cellipont Bioservices
Cenexi SAS
Central Glass Germany GmbH
Centrient Pharmaceuticals Netherlands BV
Cevec Pharmaceuticals GmbH
Charles River Laboratories International Inc
Chemic Laboratories Inc
China Gateway Pharmaceutical Development Co Ltd
ChrysCapital Management Company
Cinven Ltd
CJ Group
Clean Biologics SAS
Clinigen Ltd
CMAB Biopharma Inc
Cobra Biologics Ltd
Cognate BioServices Inc
Corden Pharma International GmbH
Corealis Pharma Inc
CoreRx Inc
Corona Remedies Pvt Ltd
CrystalGenomics Inc
Curapath SL
Curia Global Inc
Curida AS
Cytiva
Danaher Corp
Delpharm SAS
Delphi Genetics SA
Diatec Monoclonales AS
Drug Development Solutions Ltd
DRUGSTORE MORI co..,Ltd
Eczacibasi Holding AS
Eden Biologics Inc
Edgewater Capital Partners LP
EirGenix Inc
EKG Life Science Solutions LLC
Elanco Animal Health Inc
Element Materials Technology BV
Element Materials Technology Group Holdings Ltd
Enaltec Labs Pvt Ltd
Encube Ethicals Pvt Ltd
Enzychem Lifesciences Corp
Erbi Biosystems Inc
ERYTECH Pharma SA
Esteve Quimica SA
Ethypharm SAS
Eucodis Bioscience GmbH
EuroAPI SAS
Eutech Scientific Services Inc
Everstone Capital Asia Pte Ltd
Evotec SE
Exelead Inc
Expression Systems LLC
Fagron NV
Fertin Pharma AS
Flamma SpA
Flerie Invest AB
Florintree Advisors Private Limited
Forge Biologics Inc
Formulated Solutions LLC
Foster Delivery Science Inc
French Tech Sovereignty
Fresenius Kabi AG
FSN Capital VI
Fujian Kerui Pharmaceutical Co Ltd
Fujifilm Holdings Corp
Galbraith Laboratories Inc
GC Corp
GEM Global Yield LLC SCS
Genezen Laboratories Inc
GenIbet Biopharmaceuticals SA
GenNx360 Capital Partners, L.P.
Genome & Co
Genscript Biotech Corp
Gensenta Ilac Sanayi ve Ticaret AS
GL Chemtec International Ltd
Gland Pharma Ltd
Global One Healthcare Holding LLC
GNS Holdings Limited
Goldman Sachs Asset Management LP
Great Point Partners, LLC
Green Cross Cell Corp
H.I.G. Capital LLC
HBM Healthcare Investments AG
Hbm Holdings Ltd
Hepatic Cell Therapy Support SA
Hillhouse Capital Group
Hubei Yuyang Pharmaceutical Co Ltd
Ice Group AS
Idifarma Desarrollo Farmaceutico SL
Ilya Pharma AB
ImmunityBio Inc
Impact Analytical Inc
Ind-Swift Ltd
Industria Chimica Emiliana SpA
Infinity Laboratories
Inflexion Buyout Fund VI
Inflexion Enterprise Fund V
Inobic (Asia) Company Limited
Intas Pharmaceuticals Ltd
Intrum AB
InvAscent
IPCA Laboratories Ltd
iPharma Labs Inc
IriSys LLC
Japan Tissue Engineering Co Ltd
Jitsubo Co Ltd
Kartesia Advisor LLP
Kayaku Co Ltd
KCAS Bioanalytical & Biomarker Services
Keensight Capital
Kindeva Drug Delivery LP
Kiniciti LLC
KKR & Co Inc
Laboratorio Micro-Bios SL
LakePharma Inc
Leiters
Leonard Green & Partners LP
Leukocare AG
Lincoln Pharmaceuticals Ltd
List Biological Laboratories Inc
Lonza Group Ltd
Lotte Corp
Lotus Pharmaceutical Co Ltd
LTS Lohmann Therapie-Systeme AG
LX International Corp
Lyka Labs Ltd
Lyophilization Services of New England Inc
Mabxience Holding SL
Malladi Drugs & Pharmaceuticals Ltd
Management Team-Skyepharma Production SAS
Marksans Pharma Ltd
Meditab Specialities Pvt. Ltd.
Merck KGaA
Metrics Contract Services
MGC Pharmaceuticals Ltd
MicroBiopharm Japan Co Ltd
MicroConstants Inc
MidCap Financial Services LLC
Millstone Medical Outsourcing LLC
Mipharm SpA
Murano Bidco Ltd
Mycoscience Inc
Nanosyn Inc
National Resilience Inc
Nature Technology Corp
Ncardia Services BV
NextPharma Technologies GmbH
NextPharma Technologies Holding Ltd
Nichepharm Lifesciences Pvt Ltd
Nissin Pharmaceutical Co Ltd
Noramco Inc
Nordic BioAnalysis AB
Norgine BV
NovaQuest Capital Management LLC
Novartis AG
Novartis Gene Therapies
Novartis Ringaskiddy Ltd
Novitium Pharma LLC
Novo Holdings AS
NPO Petrovax Pharm
Nutra-Med Packaging Inc
NUVISAN Pharma Holding GmbH
Nuvo Pharmaceuticals Inc
Ology Bioservices Inc
Optimus Pharma Pvt Ltd
Orchid Pharma Ltd
Organix Inc
Organon & Co
Ortiv-Q3 Research Pvt Ltd
Osmotica Pharmaceutical Corp
Outlook Therapeutics Inc
Oxford Genetics Ltd
Pace Analytical Life Sciences LLC
Pace Analytical Services LLC
PAG
Panacea Biotec Ltd
Pangen Biotech Inc
Par Pharmaceutical Inc
PCI Pharma Services
Pepscan Holding NV
Petrichor Healthcare Capital Management
Pfizer Inc
Pharma Packaging Solutions
Pharmaron Beijing Co Ltd
Pharmax Pharmaceuticals FZ-LLC
Philip Morris International Inc
Phosphorex Inc
Pillar5 Pharma Inc
Piramal Pharma Solutions Inc
Pluristyx Inc
Polyplus-Transfection SA
Porton Pharma Solutions Ltd
PPD Inc
Praxis Packaging Solutions
Precision NanoSystems Inc
ProtaGene GmbH
Provepharm life Solutions SA
Psycheceutical
PT Kimia Farma Tbk
PT Pyridam Farma Tbk
Q1 Scientific Ltd
Quay Pharmaceuticals Ltd
Quinta-Analytica Sro
Quotient Sciences Alnwick Ltd
Quotient Sciences Ltd
Recipharm
Recipharm AB
Relief Therapeutics Holding AG
RheinCell Therapeutics GmbH
Rigenerand Srl
Rubicon Research Pvt Ltd
Sakar Healthcare Ltd
Sandoz Canada Inc
Sannova Analytical Inc
Sanofi
Sanwa Kagaku Kenkyusho Co Ltd
SCA Pharmaceuticals Inc
Searchlight Pharma Inc
Sekhmet Pharmaventures Pvt Ltd
Sekisui XenoTech LLC
SENSILAB Polska Sp zoo SKA
SEQENS
Seran BioScience LLC
Serum Institute of India Pvt Ltd
Sever Pharma Solutions AB
SFW Capital Partners, LLC
SGS SA
Shanghai MicroPort Medical Group Co Ltd
Shinshin Pharmaceutical Co Ltd
Signet Healthcare Partners
Skyepharma Production SAS
Snapdragon Chemistry Inc
Societal CDMO Inc
Softgel Healthcare Pvt Ltd
Solvias AG
Sotax AG
Spera Pharma Inc
SteriPack Group
Sterling Pharma Solutions Ltd
Strem Chemicals Inc
Strides Pharma Science Ltd
Sunsho Pharmaceutical Co Ltd
Suven Pharmaceuticals Ltd
Suzhou Fifth Pharmaceutical Factory Co Ltd
Suzhou Linhua Medical Equipment Co Ltd
Swissfillon AG
Symed Laboratories Ltd
Symeres
Synexa Life Sciences BV
Syngene International Ltd
Syntone Ventures LLC
SYRINX Bioanalytics Oy
Takeda Pharmaceutical Co Ltd
Tapemark Co
Tea Capital Partners Co Ltd
Teijin Ltd
Teligent Inc
ten23 Health AG
Tentamus Group GmbH
Terry Gou
tesa Labtec GmbH
Teva Pharmaceutical & Chemical (Hangzhou) Co Ltd
Tevapharm India Private Limited
The Capital Group Companies, Inc.
The Carlyle Group Inc.
The Ritedose Corp
Thermo Fisher Scientific Inc
Tjoapack BV
TOT Biopharm Co Ltd
Towa Pharmaceutical Co Ltd
TRC Capital Corp
Trirx Pharmaceutical Services LLC
True North Managers LLP
TWi Pharmaceuticals Inc
Undisclosed
Uniao Quimica Farmaceutica Nacional SA
Unither Pharmaceuticals SAS
Upperton Ltd
Uquifa SA
Vanamali Organics Pvt Ltd
Vectura Group Plc
Veeda Clinical Research Ltd
Velesco Pharmaceutical Services LLC
V-Ensure Pharma Technologies Pvt Ltd
Vibalogics GmbH
Vici Health Sciences LLC
Vigene Biosciences Inc (Inactive)
Vikas LifeCare Ltd
ViruSure GmbH
Vitruvian Partners LLP
Vivitide LLC
Viyash Life Sciences Pvt Ltd
Wacker Biotech US Inc
Wacker Chemie AG
Watson Pharma Pvt Ltd
Wavelength Pharmaceuticals
Welsh, Carson, Anderson & Stowe
Woerwag Pharma GmbH & Co KG
WuXi AppTec Co Ltd
WuXi Biologics Cayman Inc
WuXi STA (Shanghai) Co Ltd
WuXi Vaccines Co Ltd
Xpress Biologics SA
Yapan Bio Pvt Ltd
Yonsung Fine Chemicals Co Ltd
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Zollaris Laboratories Corp
Zydus Lifesciences Ltd

Table of Contents

  • 1. About GlobalData
  • 2. Table of Contents
  • 3. Executive Summary
  • 4. Players
  • 5. Technology Briefing

    • 5.1. Deal types

  • 6. Trends
  • 7. Industry Analysis

    • 7.1. Objectives and methodology
    • 7.2. Overview of M&A activity 2021–22
    • 7.3. Target characteristics

      • 7.3.1. Acquirer characteristics
      • 7.3.2. Geography
      • 7.3.3. Top acquirers
      • 7.3.4. Catalent’s deal activity
      • 7.3.5. Recipharm’s deal activity
      • 7.3.6. Segment close-ups of M&A activity, 2021–22

    • 7.4. Deal advisors

      • 7.4.1. Top financial advisors
      • 7.4.2. Top legal advisors

    • 7.5. Valuations
    • 7.6. Facility acquisitions
    • 7.7. What it means
    • 7.8. The outlook for M&A

      • 7.8.1. API—biologic targets
      • 7.8.2. API—cell and gene therapy targets

  • 8. Value Chain
  • 9. Companies
  • 10. Appendix

    • 10.1. Methodology
    • 10.2. Bibliography
    • 10.3. Primary research – key opinion leaders
    • 10.4. Further reading

  • 11. About the Authors
  • 12. Contact Us

Table

Table 1: CMO M&A trends, 2021–22

Table 2: Company acquisitions by target service offering and year, 2018–22

Table 3: Company acquisitions by target service offering and target ownership, 2021–22

Table 4: Company acquisitions by target service offering and deal region, 2021–22

Table 5: Company acquisitions by target service offering and acquirer ownership, 2021–22

Table 6: Services deals with known transaction value and multiples, 2021–22

Table 7: Facility acquisitions by CMOs, 2021–22

Table 8: Acquisitions by PE firms, 2021–22

Table 9: Potential targets: API—biologic (protein & peptide) service providers

Table 10: Potential targets: API—biologic (gene and cell therapy) service providers

Table 11: Company acquisitions and private equity deals, 2021–22

Table 12: Further reading

Figures

Figure 1: CMO M&A activity by year, 2018–22

Figure 2: Leading acquirers in the global pharma CMO industry, 2021–22

Figure 3: Top M&A trends in the CMO industry, 2021–22

Figure 4: CMO M&A activity, 2021–22

Figure 5: CMO M&A activity by year, 2018–22

Figure 6: CMO M&A activity percentage change by year, 2018–22

Figure 7: Company acquisitions by target service offering, 2021–22

Figure 8: Company acquisitions by target ownership, 2021–22

Figure 9: Company acquisitions by target ownership and service type, 2021–22

Figure 10: Acquisition targets by sophistication of capabilities, 2021–22

Figure 11: Number of acquisitions 2021–22 by acquirer’s core business

Figure 12: Number of acquisitions by acquirer’s ownership

Figure 13: Number of acquisitions by acquirer’s ownership and target service type

Figure 14: Number of acquisitions by top deal countries, 2021–22

Figure 15: Most active acquirers, 2021–22

Figure 16: Dose forms manufactured by acquired dose manufacturers, 2021–22

Figure 17: Top financial advisors to company acquisitions, 2021–22

Figure 18: Top legal advisors to company acquisitions, 2021–22

Figure 19: Pharma CMO facility acquisitions, 2021–22

Figure 20: The contract manufacturing value chain

Frequently asked questions

Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition thematic reports
Currency USD
$4,995

Can be used by individual purchaser only

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition in real time.

  • Access a live Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.